Navigation Links
AlphaVax Announces Results From Phase 1 Influenza Vaccine Clinical Trial
Date:10/31/2007

RESEARCH TRIANGLE PARK, N.C., Oct. 31 /PRNewswire/ -- AlphaVax, Inc. announced today that it has concluded a phase 1 clinical trial in 216 volunteers of an influenza vaccine based on its proprietary replicon vector platform. This study was designed to further assess the properties of this unique vector system as well as the feasibility of its application to influenza vaccines.

The study was a placebo-controlled, randomized, double-blind trial in healthy adults, 18-40 years old, which evaluated the safety and humoral and cellular immune responses after one or two inoculations. The replicon vector expressed the hemagglutinin (HA) gene derived from the A/Wyoming (H3N2) strain of influenza virus. The vaccine was administered either subcutaneously or intramuscularly at two dosage levels, and was found to be safe and well tolerated irrespective of the route or the dose given.

Both antibody and T cell responses were efficiently stimulated and persisted for the duration of the four-month study. Among volunteers with prevaccination influenza antibody titers (measured by hemagglutination inhibition, or "HI") that were below levels thought to be protective, 77% and 80% of these individuals receiving a single low or high dose, respectively, responded with protective HI antibody titers. A second immunization in these individuals increased seroprotective responses to 86% for both dosage levels. A rapid and dose-dependent T cell response (defined in antigen-specific IFN-gamma ELISPOT assays) was also observed and remained significantly elevated for at least four months. A second immunization extended the duration, but not the magnitude of these T cell responses. For both antibody and cellular responses, there was no significant difference observed between subcutaneous and intramuscular vaccinations.

"We were pleased to see the balanced immune response consisting of both humoral and cellular responses", said Dr. Jonathan Smith, CSO at AlphaVax. "Comparable
'/>"/>

SOURCE AlphaVax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... Sept. 17, 2014  Dr. Stephen Loyd , ... House today for National Recovery Month, stars in a ... released today. Consumer advocates were also joined by a ... out after losing her fiancée because of a preventable ... had a history of crack cocaine abuse. Proposition 46 ...
(Date:9/17/2014)... Bronstein, Gewirtz & Grossman, LLC is investigating ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... advised to contact Peretz Bronstein or his ... info@bgandg.com or 212-697-6484. The investigation focuses ... violated federal securities laws. On September 16, ...
Breaking Medicine Technology:BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Virtual CME, LLC , a leading provider in ... of the industry,s first online, image based CME accredited ... of streaming video, 3D visualization cloud computing, and webinars, ... "Realizing that training in medical imaging is a ...
... Va., Aug. 26, 2011 Today, Medicomp Systems announced ... its new version of the powerful MEDCIN Engine®. ... that adapts to the unique clinical presentation of each ... for compliance and reimbursement. The MEDCIN Engine currently includes ...
Cached Medicine Technology:Medicomp Releases ICD-10-CM with New Version of the Powerful MEDCIN Engine® 2
(Date:9/17/2014)... Leading eco-friendly beauty brand , Lotus Moon, ... vegan and gluten-free Sugar Cane Fruit Mask. Their newest ... skincare testers were looking for. , “My goal ... that provided results, and I think I accomplished it,” ... Mask combines Willow bark (Salix Alba extract), a natural ...
(Date:9/17/2014)... 2014 The in vitro diagnostics (IVD) ... market, focusing on molecular diagnostics for conditions such as ... testing. The IVD market value is projected to be ... 2017. The major drivers of the market’s growth include ... is evidenced by the explosion for raid and minimally-invasive ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Managing diabetes, quitting smoking, ... weight can reduce the risk for dementia -- even ... The World Alzheimer Report 2014, commissioned by Alzheimer,s Disease ... dementia by 50 percent. The study noted that obesity ... diabetes as well as high blood pressure. ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... and dieters who turn to artificial sweeteners to soothe ... favors, a new Israeli study suggests. Artificial sweeteners ... no calories, researchers found in human and mouse studies. ... alter the bacteria residing in the intestines in ways ...
Breaking Medicine News(10 mins):Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 2Health News:Artificial Sweeteners May Raise Blood Sugar Levels: Study 3
... may benefit from HPV vaccine, study finds , TUESDAY, June ... for women aged 24 to 45 who aren,t already infected ... cancer and other cervical diseases. , That,s the finding from ... Bogota, Columbia, who noted that women,s rising age at first ...
... 2, 2009 Because bleeding from the reproductive tract ... women who exhibit menorrhagia, or excessive bleeding after their ... In order to address important issues related to the ... with bleeding disorders, a consensus conference was convened. Results ...
... use a new, cutting edge diagnostic technology to fight serious ... , WOBURN, Mass., and VEDBAEK, Denmark, June 2 AdvanDx ... Georgia has implemented AdvanDx,s PNA FISH(R) tests to identify bloodstream ... help their physicians, pharmacists and nurses improve care and outcomes ...
... Reporting Now Available Through CSC,s FirstPortfolio Offering , ... CSC ) today announced that it has ... to include fully integrated Medicare Secondary Payer (MSP) reporting ... of applications hosted and maintained by CSC. , ...
... Couple,s Struggle with Alzheimer,s , , WASHINGTONVILLE, N.Y., June 2 ... over 5 million Americans currently living with Alzheimer,s disease and the ... to announce the release of her book, "Released to the Angels: ... ). , , "Released to the Angels" is an ...
... 2 Rules-Based Medicine, Incorporated (RBM), the leading biomarker ... has joined the Company as vice president, clinical diagnostics. ... as RBM commercializes new biomarker-based diagnostic tests. ... biomarker assays for improved drug development, has programs to ...
Cached Medicine News:Health News:Cervical Cancer Vaccine Not Just for Teens 2Health News:Experts reach consensus on diagnosis and treatment of bleeding disorders in women 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:CSC Offers Medicare Secondary Payer Reporting to Health Plans 2Health News:The Unexpected Gifts of Alzheimer's 2Health News:The Unexpected Gifts of Alzheimer's 3Health News:Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business 2
... semi-dry electrophoretic transfer cell and PowerPac ... Efficient Transfers. Minimal Buffer Requirements. ... and Reliable Transfers. Single-Step Locking ... Capacity to Transfer Multiple Gels. ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
PosiBlot 30-30 Sponges...
PosiBlot 30-30 Pads...
Medicine Products: